Compare Ascendis Pharma A/S (ASND) vs Jones Lang LaSalle Inc (JLL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Jones Lang LaSalle Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Jones Lang LaSalle Inc trades at $324.44 (market cap $15.05B). The key difference: Ascendis Pharma A/S is the larger of the two by market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Jones Lang LaSalle Inc nearer its low. Which is the better fit depends on your goals.
| ASND | JLL | |
|---|---|---|
Market Cap | $17.74B | $15.05B |
Sector | Health | Real Estate |
52-Week High | $277.18 | $358.66 |
52-Week Low | $163.32 | $248.95 |
Enterprise Value | $18.11B | $18.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
JLL trades at $324.44, showing modest daily gains with strong technical momentum and bullish moving averages. The company demonstrates solid fundamental improvement with revenue growth to $26.12B in 2025 and consistent earnings beats. Recent news highlights significant financing deals and Fortune 500 ranking improvement, reflecting strong business execution in commercial real estate services.
JLL presents a compelling investment case with 25% upside to consensus price target of $405.50, supported by improving profitability and positive analyst sentiment. Key risks include commercial real estate market cyclicality and competitive pressures. The stock's current valuation metrics (P/E 17.45, P/S 0.58) appear reasonable given growth prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Jones Lang LaSalle Inc
Jones Lang LaSalle provides a wide range of real estate-related services to owners, occupiers, and investors worldwide, including leasing, property and project management, and capital markets advisory. JLL's investment management arm, LaSalle Investment Management, manages over $70 billion for clients across diverse public and private real estate strategies.
Read more on JLL →
